Artivion, Inc. $AORT Stock Holdings Trimmed by GW&K Investment Management LLC

GW&K Investment Management LLC reduced its position in Artivion, Inc. (NYSE:AORT) by 10.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 753,752 shares of the company’s stock after selling 90,155 shares during the quarter. GW&K Investment Management LLC owned approximately 1.59% of Artivion worth $34,379,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Verition Fund Management LLC increased its holdings in Artivion by 1.6% in the third quarter. Verition Fund Management LLC now owns 16,912 shares of the company’s stock valued at $716,000 after buying an additional 274 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in Artivion by 6.2% in the third quarter. PNC Financial Services Group Inc. now owns 8,232 shares of the company’s stock valued at $349,000 after buying an additional 477 shares during the last quarter. Arizona State Retirement System increased its holdings in Artivion by 4.6% in the fourth quarter. Arizona State Retirement System now owns 11,235 shares of the company’s stock valued at $512,000 after buying an additional 494 shares during the last quarter. Van ECK Associates Corp increased its holdings in Artivion by 19.0% in the third quarter. Van ECK Associates Corp now owns 3,176 shares of the company’s stock valued at $134,000 after buying an additional 506 shares during the last quarter. Finally, Aster Capital Management DIFC Ltd grew its holdings in shares of Artivion by 402.3% during the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after purchasing an additional 519 shares during the last quarter. 86.37% of the stock is owned by institutional investors.

Artivion Stock Performance

Shares of NYSE AORT opened at $20.48 on Thursday. The company has a current ratio of 3.86, a quick ratio of 2.80 and a debt-to-equity ratio of 0.48. The stock has a 50 day simple moving average of $29.52 and a 200-day simple moving average of $37.33. The company has a market cap of $994.29 million, a PE ratio of 85.35 and a beta of 1.26. Artivion, Inc. has a 12-month low of $19.16 and a 12-month high of $48.25.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Stifel Nicolaus set a $45.00 target price on Artivion in a report on Monday, June 1st. Wall Street Zen lowered Artivion from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Citizens Jmp lowered their target price on Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a report on Friday, May 8th. Weiss Ratings lowered Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday. Finally, Needham & Company LLC lowered their target price on Artivion from $58.00 to $44.00 and set a “buy” rating for the company in a report on Friday, May 8th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Artivion currently has an average rating of “Moderate Buy” and a consensus price target of $46.17.

Artivion Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.